GLP-1 RECEPTOR AGONIST AND USE THEREOF

The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GL...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Jung Ho, JE, In-gyu, JEON, Woo Jin, IM, A-rang, SHIN, Jae Eui, CHANG, Min Whan, KIM, Kyeojin, KIM, Jeong-geun, JEONG, Jin Ah, KWON, Sung Wook, LEE, Jin Hee, JANG, Eun Hye, LEE, Myong Jae, SOHN, Te-ik, OH, Changmok, HONG, Changhee, HONG, Da Hae, KIM, Gunhee, PARK, Jung-eun, CHOI, Ji Hye, HEO, Jaeho, YOO, Yeongran, AN, Kyung Mi, JUN, Yearin, YOON, Hong Chul
Format Patent
LanguageEnglish
French
German
Published 01.11.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.
AbstractList The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.
Author LEE, Myong Jae
KIM, Gunhee
JEON, Woo Jin
HEO, Jaeho
OH, Changmok
HONG, Da Hae
IM, A-rang
KWON, Sung Wook
CHOI, Ji Hye
JEONG, Jin Ah
KIM, Jung Ho
SHIN, Jae Eui
PARK, Jung-eun
HONG, Changhee
CHANG, Min Whan
KIM, Kyeojin
YOON, Hong Chul
JANG, Eun Hye
SOHN, Te-ik
YOO, Yeongran
JUN, Yearin
JE, In-gyu
AN, Kyung Mi
LEE, Jin Hee
KIM, Jeong-geun
Author_xml – fullname: KIM, Jung Ho
– fullname: JE, In-gyu
– fullname: JEON, Woo Jin
– fullname: IM, A-rang
– fullname: SHIN, Jae Eui
– fullname: CHANG, Min Whan
– fullname: KIM, Kyeojin
– fullname: KIM, Jeong-geun
– fullname: JEONG, Jin Ah
– fullname: KWON, Sung Wook
– fullname: LEE, Jin Hee
– fullname: JANG, Eun Hye
– fullname: LEE, Myong Jae
– fullname: SOHN, Te-ik
– fullname: OH, Changmok
– fullname: HONG, Changhee
– fullname: HONG, Da Hae
– fullname: KIM, Gunhee
– fullname: PARK, Jung-eun
– fullname: CHOI, Ji Hye
– fullname: HEO, Jaeho
– fullname: YOO, Yeongran
– fullname: AN, Kyung Mi
– fullname: JUN, Yearin
– fullname: YOON, Hong Chul
BookMark eNrjYmDJy89L5WRQc_cJ0DVUCHJ1dg0I8Q9ScHT39_MMDlFw9HNRCA12VQjxcA1y9XfjYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgEmBqaWlkaWjibGRCgBAD4oJKw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate GLP-1-REZEPTORAGONISTEN UND VERWENDUNG DAVON
AGONISTE DU RÉCEPTEUR GLP-1 ET SON UTILISATION
ExternalDocumentID EP4059929A4
GroupedDBID EVB
ID FETCH-epo_espacenet_EP4059929A43
IEDL.DBID EVB
IngestDate Fri Aug 30 05:42:50 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP4059929A43
Notes Application Number: EP20200886669
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231101&DB=EPODOC&CC=EP&NR=4059929A4
ParticipantIDs epo_espacenet_EP4059929A4
PublicationCentury 2000
PublicationDate 20231101
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 20231101
  day: 01
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Ildong Pharmaceutical Co., Ltd
RelatedCompanies_xml – name: Ildong Pharmaceutical Co., Ltd
Score 3.496441
Snippet The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title GLP-1 RECEPTOR AGONIST AND USE THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231101&DB=EPODOC&locale=&CC=EP&NR=4059929A4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT4MwFH6Z06g3nZrNX-nBcCMOaMEdiGFQhsYBYczstsBok13m4jD--z6QTS96a9rktX3p63uv7fcV4K7iqDSlNFWNFkylmc7UQSH6asEWVqYLQ-o1jnscmsGUPs_YrAXLLRam5gn9rMkR0aIWaO9lvV-vfw6xvPpt5eY-X2LV26Of2p7SZMcYrOASU7yhzePIi1zFdbGkhIlNKx4SfeDQPdjHKNqqjIG_DitQyvq3R_FP4CBGYavyFFpi1YEjd_vxWgcOx819NxYb09ucgTJ6iVWNJNzlcRolxBlF4dMkJU7okemEkzTgCY_8cyA-T91AxQ7nu8nNebwbmnEBbcz5RReIpmc5lcwo-kKjViYfNCkNExVeZCJn1OxB708xl_-0XcFxpaVvMN01tMv3D3GDXrXMb2t9fAHnvXfi
link.rule.ids 230,309,783,888,25576,76882
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8gGvFNUQN-9sHsbZFt3YCHxYytYyhsyxiGN7KxNuEFicz473ubA33Rt0ubXNtLr3fX9ncH8FDkqDSEMGSFZrpME1WX-xnvyJm-7CYq14Ra4rgnvuHN6PNcn9dgtcPClHlCP8vkiKhRS9T3vDyvNz-XWE75t3L7mK6w6e3JjU1HqqJjdFZwi0nOwGRh4AS2ZNtISX5k0iIPidq36AEcoofdK4odsNdBAUrZ_LYo7ikchchsnZ9Bja-b0LB3hdeacDyp3ruRrFRvew7ScBzKComYzcI4iIg1DPzRNCaW75DZlJHYYxEL3AsgLottT8YBF_vFLVi4n5p2CXWM-XkLiKImKRW6lnW4QruJ6ClCaAYKPEt4qlOjDe0_2Vz903cPDS-ejBfjkf9yDSeFxL6BdTdQz98_-C1a2Dy9K2XzBa6tetI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=GLP-1+RECEPTOR+AGONIST+AND+USE+THEREOF&rft.inventor=KIM%2C+Jung+Ho&rft.inventor=JE%2C+In-gyu&rft.inventor=JEON%2C+Woo+Jin&rft.inventor=IM%2C+A-rang&rft.inventor=SHIN%2C+Jae+Eui&rft.inventor=CHANG%2C+Min+Whan&rft.inventor=KIM%2C+Kyeojin&rft.inventor=KIM%2C+Jeong-geun&rft.inventor=JEONG%2C+Jin+Ah&rft.inventor=KWON%2C+Sung+Wook&rft.inventor=LEE%2C+Jin+Hee&rft.inventor=JANG%2C+Eun+Hye&rft.inventor=LEE%2C+Myong+Jae&rft.inventor=SOHN%2C+Te-ik&rft.inventor=OH%2C+Changmok&rft.inventor=HONG%2C+Changhee&rft.inventor=HONG%2C+Da+Hae&rft.inventor=KIM%2C+Gunhee&rft.inventor=PARK%2C+Jung-eun&rft.inventor=CHOI%2C+Ji+Hye&rft.inventor=HEO%2C+Jaeho&rft.inventor=YOO%2C+Yeongran&rft.inventor=AN%2C+Kyung+Mi&rft.inventor=JUN%2C+Yearin&rft.inventor=YOON%2C+Hong+Chul&rft.date=2023-11-01&rft.externalDBID=A4&rft.externalDocID=EP4059929A4